Bioactive Hydrogel
AssigneeZetascience GmbH
InventorsCarsten Werner, Uwe Freudenberg, Dorit Meinhold, Marie-Francoise Gouzy, Petra Welzel
Life of this patent
Estimating the term…
Abstract
The invention relates to a bioactive hydrogel as a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound directly by reaction of the carboxyl groups activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimides/N-hydroxysulfosuccinimide (EDC/s-NHS) with the terminal amino groups of the polyethylene glycol covalently by amide bonds.
Claims20
A bioactive hydrogel comprising a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound (a) covalently by amide bonds by direct reaction of the carboxyl groups activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimides/N-hydroxysulfosuccinimide (EDC/s-NHS) with the terminal amino groups of the polyethylene glycol, or (b) covalently to the polyethylene glycol via short enzyme-cleavable peptide sequences as crosslinking molecules.
A bioactive hydrogel comprising a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound covalently to the polyethylene glycol via short enzyme-cleavable peptide sequences as crosslinking molecules.
A bioactive hydrogel comprising a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound covalently by amide bonds by direct reaction of the carboxyl groups activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimides/N-hydroxysulfosuccinimide (EDC/s-NHS) with the terminal amino groups of the polyethylene glycol.
Dependencies are inferred from the claim text.